Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 243

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 243
---
 to purchase
up to an aggregate of 81,944 common shares at an exercise of $9.60 per share in a concurrent private placement. The common warrants were
immediately exercisable upon issuance and expire five years following the date of issuance. The agreement includes customary representations,
warranties, and indemnification provisions. We agreed not to issue or announce the issuance of any common shares or equivalents for 15 days
post-closing, with certain exceptions, and not to engage in variable rate transactions for one-year post-closing. The offering generated
gross proceeds of approximately $786,660.

On September 16, 2024,
we entered into a warrant amendment agreement with an institutional investor to amend warrants to purchase up to 172,836 common shares,
adjusting the definition of a “ Fundamental Transaction” and the exercise price to CHF 0.80. In exchange for the September
Warrant Amendment, the Company agreed to adjust the exercise price in the Common Warrants to CHF 0.02, and following the Company increasing
its authorized Common Shares, issued to the investor, pre-funded warrants to purchase up to 191,431 shares of Common Shares, or the Pre-Funded
Warrants.

On
October 9, 2024, we entered into a securities purchase agreement with certain accredited investors. Under this agreement, we issued and
sold 806,452 common shares and warrants to purchase an additional 806,452 common shares, at a combined purchase price of $3.97, for aggregate
gross proceeds of $3.2 million. The warrants have a term of five years and an exercise price of $4.25 per share. Investors were granted
the right to participate in up to 50% of future offerings for one year following the closing. We also agreed not to enter into an equity
line of credit or similar agreement without the consent of the majority of the preferred shareholders. The transaction closed on October
10, 2024.

Also
on October 9, 2024, we entered into a securities purchase agreement with an accredited investor to satisfy $4.0 million of our debt by
issuing 806,452 newly designated convertible preferred shares at a purchase price of $4.96 per share. The preferred shares have a conversion
price of $4.96 per share. The investor was granted the right to purchase up to an additional $10.0 million worth of convertible preferred
shares starting six months after the closing and continuing as long